E. Mortensen

Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

A. Bredenoord, E. Dellon, I. Hirano, 2023, The lancet. Gastroenterology & hepatology.

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

G. Yancopoulos, M. Bafadhel, S. Bhatt, 2023, The New England journal of medicine.

Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population

P. Polanco, M. Porembka, M. Augustine, 2022, Annals of Surgical Oncology.

Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study

A. Bredenoord, I. Hirano, A. Shabbir, 2023, Gut.